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Abstract
Objective
To evaluate the influence of sociodemographic, clinical, and epidemiological factors
in AIDS patients survival in a reference hospital.
Methods
A sample of 502 adult AIDS patients out of 1,494 AIDS cases registered in a hospital
in Fortaleza, Brazil, was investigated between 1986 and 1998. Sixteen cases were
excluded due to death at the moment of the AIDS diagnosis and 486 were analyzed in
the study. Socioeconomic and clinical epidemiological were the variables studied.
Statistical analysis was conducted using the Kaplan-Meier survival analysis and the
Cox proportional hazards model.
Results
Three hundred and sixty two out of the 486 patients studied took at least one antiretroviral
drug and their survival was ten times longer than those who did not take any drug
(746 and 79 days, respectively, p <0.001). Patients who took two nucleoside reverse
transcriptase inhibitors (NRTI) plus protease inhibitor were found to have higher
survival rates (p <0.001). The risk of dying in the first year was significantly lower
for patients who took NRTI and a protease inhibitor compared to those who took only
NRTI. In addition, this risk was much lower from the second year on (0.10; 95%CI:
0.42-0.23). The risk of dying in the first year was significantly higher for less educated
patients (15.58; 95%CI: 6.64-36.58) and those who had two or more systemic diseases
(3.03; 95%CI: 1.74-5.25). After the first year post-diagnosis, there was no risk
difference for these factors.
Conclusions
Higher education revealed to exert a significant influence in the first-year survival.
Antiretroviral drugs had a greater impact in the survival from the second year on. A
more aggressive antiretroviral therapy started earlier could benefit those patients.
Resumo
Objetivo
Avaliar, em um hospital de referência, a influência de fatores sociodemográficos e
clínico-epidemiológicos na sobrevivência de pacientes com Aids.
Métodos
Foi estudada uma amostra de 486 adultos com Aids atendidos em hospital de
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Most literature studies on AIDS patient survival
report cases in developed countries.14,15 A decreasing
mortality rate in relation to total cases has been
registered in Brazil every year despite the scarcity of
studies,2,6 especially in the northeast region, that
would allow measuring the impact of antiretroviral
drugs and other variables on patient survival. In
addition, new diagnostic techniques, such as CD4+
count and viral load, have been employed recently in
an attempt to improve the patient’s prognosis with
the introduction of antiretroviral treatments timely.
Since 1991, antiretroviral drugs are available at no
cost to all patients in Brazil.
Fortaleza, the capital of the state of Ceará, is one of
the largest cities in the northeast region. The AIDS
epidemic in this city has shown a trend towards an
increasing number of cases since it was first
recognized in 1983. A predominance of homosexual/
bisexual transmission and a steady rise in incidence
among heterosexual individuals, chiefly among
women, have been evidenced. This disease profile
differs from that of other regions in Brazil, especially
the southeast region where most cases are
concentrated. There have been registered a significant
number of AIDS cases among intravenous drug users
and a marked decrease in male-to-female ratio.
Studies relating social demographic and clinical
epidemiological factors to the survival of AIDS
patients have not yet been conducted in the state.
Hence, the present study intends to evaluate the impact
of these variables on patient survival in the region.
referência no Ceará, entre 1986 e 1998. Foram avaliadas as variáveis
socioeconômicas e clínico-epidemiológicas. A análise foi realizada pelo método
Kaplan-Meier e por regressão de Cox.
Resultados
Dos 486 pacientes estudados, 362 utilizaram pelo menos uma droga anti-retroviral e
tiveram sobrevida dez vezes maior que os que não a utilizaram (746 e 79 dias,
respectivamente; p<0,001). O risco de morrer, no primeiro ano, foi significativamente
menor (0,25; IC95%: 0,12-0,50) para os que fizeram uso de dois inibidores de
transcriptase reversa ou HAART e menor a partir do segundo ano (0,10; IC95%:0,42-
0,23) em relação aos que não os usaram. Indivíduos sem nível universitário (15,58;
IC95%:6,64-36,58) e que apresentaram duas ou mais doenças sistêmicas (3,03;
IC95%:1,74-5,25) tiveram risco significativamente maior de morrer no primeiro
ano. Após o primeiro ano, não se observou diferença.
Conclusão
O melhor nível socioeconômico, medido indiretamente pela escolaridade, demonstrou
grande influência na sobrevivência no primeiro ano. As drogas anti-retrovirais tiveram
mais impacto na sobrevivência a partir do segundo ano, assim como igualaram o
risco de morrer de pacientes com duas ou mais doenças sistêmicas àqueles que não
tiveram nenhuma no mesmo período. Concluiu-se que uma introdução mais precoce
e mais agressiva dos anti-retrovirais poderia beneficiar os pacientes.
METHODS
Population and variables studied
Between 1986 and April 1998, 1,734 AIDS cases
were diagnosed in adults in the city of Fortaleza, of
which 1,494 (86.2%) were referred to the state
hospital, a reference center of AIDS treatment.
A random sample of 502 adult AIDS patients was made
up in alphabetical order. Sixteen individuals diagnosed
at death as having AIDS (3.18%) were excluded,
remaining 486 in the study. Of these, 362 patients
received antiretroviral therapy and 124 did not.
The variables studied to assess a potential
relationship with patient survival were:
a) Social demographics: sex; age at diagnosis (<30,
30-34, 35-39, and ≥40 years); educational level
(illiterate, elementary, high school, university);
place of origin (capital or interior of the state);
and socioeconomic status assessed indirectly
through city area of residence. Socioeconomic
status variable was defined according to:
educational level of the head of the family (less
than 4 years of schooling; 4 to 7 years of
schooling; and 8 or more years of schooling); per
capita income (up to half minimum salary; half
to one; one to two; two to five; five to fifteen;
fifteen to twenty; and above twenty minimum
salaries); proportion of residences with water
supply; inadequate sewage system and residences
with no garbage collection. Scores 1 to 10 were
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attributed to these variables, then added and
classified as high, medium and low according to
the patient’s area of residence.
b) Clinical epidemiological: probable form of
transmission (homosexual/bisexual, heterosexual,
or blood); CD4+ counts (CD4+ ≥100 x 106/L, first
count after AIDS diagnosis); early hemoglobin
level (≥11 g/dl and <11 g/dl); characteristic
opportunistic diseases (Kaposi’s sarcoma,
Pneumocystis carinii pneumonitis, tuberculosis,
other diseases); early presence of systemic
diseases (only one disease, two or more at the time
of diagnosis); use of antiretroviral drugs (reverse
transcriptase inhibitors + protease inhibitors or
zidovudine alone); and diagnostic criteria
(Caracas criteria9 versus CDC criteria1). See under
Discussion the possible influence of diagnostic
criteria in the survival analysis.
Statistical analyses
Survival time corresponded to the number of days
elapsed between AIDS diagnosis and death or the
number of days elapsed between diagnosis and the
last visit to the hospital for those lost to follow up or
those who were alive at the end of the study.
The impact of the variables on patient survival was
analyzed using Kaplan-Meier survival analysis
method, and any possible statistical differences
between the subgroups were evaluated using the log-
rank test. Individuals who died before the completion
of the study were considered as “failures” (n=279),
and those who remained alive or were lost during the
study period were assigned as “censored” (n=207).
For assessing the performance of predictive factors,
multivariate analysis was carried out using the Cox
proportional hazards model. The Stata version 6.0
software was used for the entire analysis.
The proportional hazard assumption was analyzed
by testing the probable interaction of variables with
time in the regression model and graphically using
the ln (-ln) survival curve.
RESULTS
The median survival for patients receiving at least
one drug compared to those who were not under any
medication was approximately 10 times higher (746
and 79 days, respectively; p<0.001).
Assuming that only patients receiving antiretroviral
drugs would be of greater significance since their
survival has been dramatically increased after the
emergence of drugs to fight AIDS, it was decided to
include in the study only these cases (362 patients:
183=failures and 179=censored).
Male-to-female case distribution in the cohorts was
of approximately 6.3:1 (Table). There was no
statistically significant difference between median
survivals of male and female patients (p=0.43).
As to the transmission category, study patients were
mainly homosexuals/bisexuals (52.0%), heterosexuals
(33.1%), and 14.8% were infected through blood
(intravenous drug users, hemophiliacs or transfused).
The median survival was not significantly different
for any of these categories (p=0.21).
There was no difference in the median survival
among different age groups (p=0.46); patients with
different AIDS-characteristic diseases (p=0.38);
patients who had one or more systemic diseases
(p=0.78); patients who had CD4+ counts ≥100 x 106/
L (p=0.12); patients who were diagnosed according
to different criteria (p=0.38); patients who lived in
the capital (p=0.11); or between patients who lived
in areas with different socioeconomic status (p=0.06).
To assess the possible effects of other confounding
survival variables the study period was divided in
two segments: patients diagnosed before 1995 and
after 1995. Survival was only assessed in patients
receiving at least one antiretroviral drug. Patients
diagnosed after 1995 showed to have higher survival
rates. However, after adjusting for therapy (reverse
transcriptase inhibitor + protease inhibitor vs. reverse
transcriptase inhibitor), only the therapy effect
remained significant. Furthermore, it was found that
the two period segments were significantly related to
therapy (p <0.001), therefore, only the variable therapy
was kept in the model and the two period segments
were discarded.
Patients who received a combined therapy of reverse
transcriptase inhibitors and protease inhibitors had
survival rates significantly greater than those receiving
only one or more reverse transcriptase inhibitors (p
<0.001), and those who had hemoglobin levels of 11
g/dl or more at the time of diagnosis (p <0.001).
Patients with two or more systemic diseases at the
time of diagnosis had a greater risk of death in the
first year compared to those who had no, or only one,
systemic disease (1.7; 95%CI: 1.1-2.9). Hemoglobin
levels equal to or greater than 11 g/dL reduced the
fatality risk of patients with more than one-year
survival. On the other hand, patients receiving
zidovudine or stavudine combined with other drug
of similar effect (didanosine, zalcitabine, lamivudine)
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*Cumulative survival median.
**Log-rank Test (1st column compares all the subgroups of each variable, 2nd column compares each of the sub3groups with
the rest, together).
***Educational level: high = University education, low = less than University education.
****Tb = Tuberculosis ; PCP = Pneumocystis carinii pneumonitis; KS = Kaposi‘s sarcoma, Others = other diseases, excluding
those cited.
*****RTI = Reverse Transcriptase Inhibitor (zidovudin, didanosin, zalcitabin, lamivudin, estavudin)
 PI = Protease Inhibitor (indinavir, saquinavir)
Note - Social-economic condition of the residential city zone = considered: per capita income in minimum salaries +
education level + water suply, inadequate drainage and garbage collection facilities The variable social-economic condition
of the area where the patient lived was defined according to: the educational level of the head of the family (less than 4 years
of schooling, 4 to 7 years of school education and 8 or more years of studies); the  per capita income (up to half of the minimum
salary, half to one, one to two, two to five, five to fifteen, fifteen to twenty and above twenty minimum salaries); proportion of
residences with water supply; inadequate drainage system and residences without garbage collection [28]. For these
variables, scores of 1 to 10 were attributed, added and classified as high, medium and low, in reference to the origin of the city
zone of each patient. All the data were from the “Fundação Instituto Brasileiro de Geografia e Estatística (IBGE)”, 1991.
N Median survival time P
Variables individuals (days)* (value)**
Coorte 362 746
Sex 0.43
Male 313 742
Female 49 1.231
Age (years) 0.46
<30 115 675 0.37
30-34 93 800 0.51
35-39 72 844 0.23
40 or + 82 663 0.37
Education level*** 0.30
High 53 1.068
Low 264 708
Social-economic status of the City zone of origin (see Note) 0.06
High 90 497 0.02
Medium 142 778 0.34
Low 86 915 0.22
Origin 0.11
Capital 324 729
Interior of State 38 831
Risk group 0.21
Homosexual/Bisexual 182 815 0.37
Heterosexual 116 743 0.70
Blood products 52 651 0.08
1ª AIDS-defining disease**** 0.38
TB alone 31 1.231 0.32
PCP alone 38 550 0.17
KS alone 13 562 0.48
Others 280 763 0.53
1ª  systemic disease 0.78
No disease 118 675 0.83
One only 152 828 0.50
Two or more 68 708 0.58
Anti-retroviral use***** <0.001
RTI + PI 130 <0.001
RTI 122 684 0.06
AZT 105 311 <0.001
Hemoglobin level (g/dl) <0.001
≥11 190 991
<11 157 459
CD4+ count 0.12
≥100 x 106/l 100
<100 x 106/l 67 1.068
Table - AIDS patients attended to a hospital of Ceará, according to the variables studied and the survival time, during the
period 1986-1998.
had a higher risk of dying in all cohorts (5.6; 95%CI:
3.3-9.7) in the first year (4.4; 95%CI: 2.2-8.8), and
more pronouncedly in the second year (8.1; 95%CI:
3.4-19.2) when compared to those receiving a
combination therapy (reverse transcriptase inhibitor
+ protease inhibitor).
CD4+ counts have been available in the public
service since July 1997 but the number of AIDS patients
who have access to this service in the hospital today is
still limited. The assessment of CD4+ together with
other significant variables resulted in great instability
in the statistical model. For that, the impact of CD4+
on the survival was analyzed in a separate model which
included the patient’s drug therapy and his/her CD4+
count (≥100 x 106/L and CD4+ <100 x 106/L). CD4+
counts were found to be a confounding effect of the
treatment, and patients with CD4 + ≥100 x 106/L had a
significantly higher survival (0.42; 95%CI: 0.20-
0.86). In addition, the fatality risk for patients receiving
one or more reverse transcriptase inhibitors associated
with other antiretroviral drugs (protease inhibitors) did
not differ in the first year (0.26; 95%CI: 0.03-2.14),
and was significantly lower (0.06; 95%CI: 0.02-0.19)
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in the second year for those who were not on protease
inhibitors, when corrected for the CD4+ counts
respectively, for the entire study period.
AIDS treatment, education level and presence of
two or more systemic diseases did not satisfy the
proportional hazards assumption of Cox model. For
that reason, an analysis of the hazard ratio was
conducted for two different periods: the first year after
diagnosis and from the second year on.
The risk of death in the first year after diagnosis for
those receiving reverse transcriptase inhibitors
combined with protease inhibitors was significantly
lower compared to that of those who did not receive
these drugs in combination (0.25; 95%CI: 0.12-0.50).
From the second year on, an even lower risk was
observed (0.10; 95%CI: 0.42-0.23).
Also, the risk of death in the first year was found to
be significantly higher for those who were university
educated (15.58; 95%CI: 6.64 -36.58) and who had
two or more systemic diseases (3.03; 95%CI: 1.74-
5.25) at the time of diagnosis. However, after the first
year, no difference was observed in the fatality risk
for any of these groups (0.61; 95%CI: 0.36-1.04 and
0.79; 95%CI: 0.47-1.33, respectively).
The adjusted survival rate for the entire period
studied was greater for patients receiving
combination therapy (reverse transcriptase inhibitor
+ protease inhibitor), for those university educated
and with up to one systemic disease at the time of
diagnosis (Figures 1, 2, and 3).
DISCUSSION
Among the variables that had a significant impact
on survival rates, the most predominant ones were:
therapy regimen, CD4+ count, education status, and
presence of systemic diseases.
Antiretroviral drugs had a significant impact on the
survival of AIDS patients admitted to the state reference
hospital. At some points in the disease course,
antiretroviral drug therapy was shown to be the best
survival predictor.3,7 It was found that antiretroviral
therapy had a greater impact from the second year
onwards. This occurrence could have some
explanations. According to the Brazilian Consensus
for Antiretroviral Therapy for HIV-infected adults and
adolescents, the introduction of antiviral treatment
depends on a variety of factors, such as viral load and
CD4+ counts.8 As a result, the entire diagnostic process
of AIDS patients takes a relatively long time and
Figure 1 - Survival of AIDS patients under anti-retroviral
therapy, 1986-1998.
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Figure 2 - Survival of AIDS patients with systemic disease,
1986-1998.
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Figure 3 - Survival of AIDS patients, according to the
educational level, 1986-1998.
High education level = University education.
Low education level = Less than university education.
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requires setting up the antiretroviral therapy regimen
as part of the patient’s routine hospital care.
Another explanation could be that, as an AIDS
opportunistic infection, pulmonary tuberculosis affects
30.9% of the diagnosed cases, and it is characterized
as an AIDS-defining disease. Disseminated tuberculosis
associated with pulmonary tuberculosis occurs in 6.4%
of the cases. To treat these patients, there is a need to
modify the antiretroviral therapeutic regimen and delay
its start to avoid drug interactions between the two
courses of therapy, which could compromise their
clinical progress due to a delay in introducing protease
inhibitors. Thus, extensive diagnostic procedures and
treatment delay, and the often concomitant occurrence
of tuberculosis could explain the greater impact on
survival from the second year onwards.
The presence of more than one systemic disease
had also an effect on the first-year survival. Those
patients diagnosed as having two or more systemic
diseases had a much greater likelihood of dying than
those who had no systemic disease or only one,
probably due to greater compromise of their immune
systems. However, such difference is not observed
from the second year onwards. For those patients with
more serious concurrent infections, a more rigorous
antiretroviral therapy regimen is immediately
established, while those who have less advanced
symptoms are put on more conservative therapeutic
schemes. Such practice may be contributing to even
out risks for survival of those patients having two or
more systemic diseases in the second year and those
having no more than one systemic disease.
Patient’s education status was used as an indirect
indicator of socioeconomic status, as only a small
percentage succeed in getting university education
in Brazil. In Ceará and its capital Fortaleza, only
0.6% and 1.7% of the population, respectively, get
to the university.4 Considering the first-year period
of the study, it was observed that the risk of dying
for those who did not have university education
was much higher than that for those who had
university education. A plausible explanation
would be the fact that, in the first year of diagnosis,
the disease exerts a greater impact on the lives of
less educated patients due to their  poor
socioeconomic conditions. From the second year
onwards, equal access to antiretroviral therapy
allied to similar compliance problems would make
both groups alike concerning biological aspects,
thus balancing out their risks. Some studies
revealed that continuous drug compliance is
essential to avoid viral resistance, which is
somewhat difficult to achieve with the current
treatment schemes. In addition, the impact of
prolonged treatment on the quality of life should
be considered carefully.13
Other variables found to be significant for survival
in other nationwide and worldwide cohort studies
were not found to have considerable effects on
survival rates of the current study cohorts. There were
no significant differences in survival rates of the
age groups studied, which is consistent with Seage
et al’s findings in Boston.15 However, other studies
have also suggested that individuals from older age
groups tend to show lower survival rates.2,14
Among the potential modes of virus exposure,
there were no differences in survival rates in the
present study. Similar results were reported in the
US,15 although European studies revealed
differences in survival rates among groups with
different viral exposures.5,11
Typical AIDS infections such as tuberculosis,
Pneumocystis carinii pneumonitis, Kaposi’s sarcoma,
and others were evaluated separately and when
compared against each other, no statistically
significant difference in survival rates was observed.
Similarly, no difference was found in survival related
to the first AIDS manifestation in Ireland. Other study
showed significant differences in survival related to
the first AIDS-defining disease.10 Patients who
developed tuberculosis as their first AIDS opportunistic
diseases revealed survival rates significantly higher
than those who did not have the disease.12
Diagnostic criteria could influence Aids survival
studies since there were several versions in the 1980s
(different versions of CDC criteria), which more
conservative compared to those of the 1990s (the
Caracas or Rio de Janeiro criteria), more well-suited
to Brazilian patients. The most recent criteria elicit
a better prognosis and can be theoretically more
adequate to diagnose Aids at an earlier stage.
Survival of the whole patients was significantly
greater among those who took any medication.
However, the survival improvement could be not
only attributed to the treatment but it seems to reflect
also changes in the diagnostic criteria. Patient who
took no medication were also the ones diagnosed
according to the 1980’s criteria, since AZT was
introduced to these patients only in the beginning
of the 1990s (only two patients took AZT in
November 1989). In further analysis, only patients
who took any medication were kept in the study,
and therefore the diagnostic criteria did not influence
the study results because starting from 1990 all AIDS
diagnoses followed the new criteria.
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In conclusion, this study revealed that
antiretroviral drugs had a significant impact on the
increased survival of AIDS patients. The same
impact was seen for higher education status and
the presence of no more than one systemic disease.
It was also observed that these variables had
differing impact on the first-year and second-year
survival rates. Better outcomes due to antiretroviral
therapy found from the second year onwards may
suggest that diagnostic procedures and the
cessation of drug treatment especially because of
frequent tuberculosis diagnosis  are prematurely
reducing the possible benefits on patient survival.
A revision of the more conservative antiretroviral
therapy procedures for patients who do not present
two or more systemic diseases in the first year after
diagnosis has to be considered since their fatality
risk from the second year post-diagnosis onwards
is balancing out to that of those who had serious
diseases, and these patients could benefit from a
more aggressive treatment. There is a need of further
studies including a larger number of patients for
whom there are CD4+ counts and viral load data in
order to study the effects of the variables found to
have significant impact on survival in the present
study. Current cohorts of AIDS patients should also
be studied as regards of their treatment compliance
since this could influence these patients’ survival.
